Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRO2TECT-CORRECTION: vadadustat versus darbepoetin alfa for correction of anemia in non-dialysis-dependent chronic kidney disease
2015-004265-81Phase 3Completed
- Sponsor
- Akebia Therapeutics
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vadadustat in Uraemic Anaemia (2 arms), sponsored by Akebia Therapeutics. Primary endpoint: Mean change in hemoglobin between baseline and the primary evaluation period. Started Apr 2016; status: completed.
02
Drugs
vadadustat
03
Conditions
Uraemic Anaemia
Beyond the preview
Go deeper on 2015-004265-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004265-81.